Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07519564) titled 'A Phase I Clinical Study to Evaluate the PK, PD, Efficacy, and Safety of GB18 Injection in Patients With Tumor Cachexia' on April 2.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Kexing Biopharm Co., Ltd.
Condition:
Cachexia
Cancer
Intervention:
Drug: GB18
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: April 30, 2026
Target Sample Size: 18
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07519564...